{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T12:21:22Z","timestamp":1768998082989,"version":"3.49.0"},"reference-count":31,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2023.13915","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T05:21:52Z","timestamp":1686806512000},"source":"Crossref","is-referenced-by-count":3,"title":["Early low blood MALT1 expression levels forecast better efficacy of PD\u20111 inhibitor\u2011based treatment in patients with metastatic colorectal cancer"],"prefix":"10.3892","volume":"26","author":[{"given":"Chuanming","family":"Li","sequence":"first","affiliation":[{"name":"Department of Anorectal Surgery, Wuhan No. 8 Hospital (Wuhan Anorectal Hospital), Wuhan, Hubei 430000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Anorectal Surgery, Wuhan No. 8 Hospital (Wuhan Anorectal Hospital), Wuhan, Hubei 430000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanli","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Wuhan No. 8 Hospital (Wuhan Anorectal Hospital), Wuhan, Hubei 430000, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2023,6,15]]},"reference":[{"key":"key20230807130139_b1-ol-26-2-13915","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1097\/DCR.0000000000001762","article-title":"On Behalf of the Clinical Practice Guidelines Committee of the American Society of Colon and Rectal Surgeons: The American Society of Colon and rectal surgeons clinical practice guidelines for the management of rectal cancer","volume":"63","author":"You","year":"2020","journal-title":"Dis Colon Rectum"},{"key":"key20230807130139_b2-ol-26-2-13915","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"key20230807130139_b3-ol-26-2-13915","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s10555-018-9748-7","article-title":"Multiple treatment lines and prognosis in metastatic colorectal cancer patients","volume":"38","author":"Carlomagno","year":"2019","journal-title":"Cancer Metastasis Rev"},{"key":"key20230807130139_b4-ol-26-2-13915","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12885-017-3925-x","article-title":"Colorectal cancer liver metastases-a population-based study on incidence, management and survival","volume":"18","author":"Engstrand","year":"2018","journal-title":"BMC Cancer"},{"key":"key20230807130139_b5-ol-26-2-13915","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/08923973.2022.2112222","article-title":"A comparison of panitumumab and cetuximab in the treatment of KRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis","volume":"45","author":"Liu","year":"2022","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"key20230807130139_b6-ol-26-2-13915","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1080\/01926230701320337","article-title":"Apoptosis: A review of programmed cell death","volume":"35","author":"Elmore","year":"2007","journal-title":"Toxicol Pathol"},{"key":"key20230807130139_b7-ol-26-2-13915","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.critrevonc.2005.06.005","article-title":"An overview of apoptosis and the prevention of colorectal cancer","volume":"57","author":"Watson","year":"2006","journal-title":"Crit Rev Oncol Hematol"},{"key":"key20230807130139_b8-ol-26-2-13915","doi-asserted-by":"publisher","first-page":"847345","DOI":"10.3389\/fimmu.2022.847345","article-title":"Programmed cell death tunes tumor immunity","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"key20230807130139_b9-ol-26-2-13915","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.3389\/fimmu.2020.01088","article-title":"Looking for the Optimal PD-1\/PD-L1 Inhibitor in Cancer Treatment: A comparison in basic structure, function, and clinical practice","volume":"11","author":"Chen","year":"2020","journal-title":"Front Immunol"},{"key":"key20230807130139_b10-ol-26-2-13915","doi-asserted-by":"publisher","DOI":"10.1007\/s11030-022-10509-2","article-title":"Progress in programmed cell death-1\/programmed cell death-ligand 1 pathway inhibitors and binding mode analysis","author":"Li","year":"2022","journal-title":"Mol Divers"},{"key":"key20230807130139_b11-ol-26-2-13915","doi-asserted-by":"publisher","first-page":"115113","DOI":"10.1016\/j.bcp.2022.115113","article-title":"Strategies for developing PD-1 inhibitors and future directions","volume":"202","author":"Chen","year":"2022","journal-title":"Biochem Pharmacol"},{"key":"key20230807130139_b12-ol-26-2-13915","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1667\/RADE-22-00061.1","article-title":"PD-1 inhibitor enhanced radiosensitivity by reactivating T cells and inducing G2\/M phase arrest in esophageal squamous cell carcinoma","volume":"198","author":"Hao","year":"2022","journal-title":"Radiat Res"},{"key":"key20230807130139_b13-ol-26-2-13915","doi-asserted-by":"publisher","first-page":"774445","DOI":"10.3389\/fonc.2021.774445","article-title":"Preliminary efficacy and safety of camrelizumab in combination with XELOX plus bevacizumab or regorafenib in patients with metastatic colorectal cancer: A Retrospective study","volume":"11","author":"Zhou","year":"2021","journal-title":"Front Oncol"},{"key":"key20230807130139_b14-ol-26-2-13915","doi-asserted-by":"publisher","first-page":"861","DOI":"10.4149\/neo_2021_201228N1415","article-title":"Efficacy and safety of regorafenib or fruquintinib plus camrelizumab in patients with microsatellite stable and\/or proficient mismatch repair metastatic colorectal cancer: An observational pilot study","volume":"68","author":"Jiang","year":"2021","journal-title":"Neoplasma"},{"key":"key20230807130139_b15-ol-26-2-13915","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3389\/fonc.2019.00396","article-title":"Review of PD-1\/PD-L1 Inhibitors in Metastatic dMMR\/MSI-H Colorectal Cancer","volume":"9","author":"Oliveira","year":"2019","journal-title":"Front Oncol"},{"key":"key20230807130139_b16-ol-26-2-13915","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","article-title":"Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer","volume":"36","author":"Overman","year":"2018","journal-title":"J Clin Oncol"},{"key":"key20230807130139_b17-ol-26-2-13915","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.7150\/ijbs.64077","article-title":"Immunotherapy in colorectal cancer: Current achievements and future perspective","volume":"17","author":"Fan","year":"2021","journal-title":"Int J Biol Sci"},{"key":"key20230807130139_b18-ol-26-2-13915","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1002\/med.21799","article-title":"MALT1 as a promising target to treat lymphoma and other diseases related to MALT1 anomalies","volume":"41","author":"Liang","year":"2021","journal-title":"Med Res Rev"},{"key":"key20230807130139_b19-ol-26-2-13915","doi-asserted-by":"publisher","first-page":"114977","DOI":"10.1016\/j.bcp.2022.114977","article-title":"Post-translational modification of MALT1 and its role in B cell- and T cell-related diseases","volume":"198","author":"Zhang","year":"2022","journal-title":"Biochem Pharmacol"},{"key":"key20230807130139_b20-ol-26-2-13915","doi-asserted-by":"publisher","first-page":"714906","DOI":"10.3389\/fmolb.2021.714906","article-title":"Integrative analysis of MALT1 as a potential therapeutic target for prostate cancer and its immunological role in pan-cancer","volume":"8","author":"Tan","year":"2021","journal-title":"Front Mol Biosci"},{"key":"key20230807130139_b21-ol-26-2-13915","doi-asserted-by":"publisher","first-page":"845048","DOI":"10.3389\/fcell.2022.845048","article-title":"Targeting MALT1 suppresses the malignant progression of colorectal cancer via miR-375\/miR-365a-3p\/NF-\u03baB Axis","volume":"10","author":"Qian","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"key20230807130139_b22-ol-26-2-13915","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41698-021-00175-2","article-title":"Knockout of immunotherapy prognostic marker genes eliminates the effect of the anti-PD-1 treatment","volume":"5","author":"Yang","year":"2021","journal-title":"NPJ Precis Oncol"},{"key":"key20230807130139_b23-ol-26-2-13915","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the eastern cooperative oncology group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"key20230807130139_b24-ol-26-2-13915","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(\u2212Delta Delta C(T)) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"key20230807130139_b25-ol-26-2-13915","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.1200\/JCO.2007.15.4138","article-title":"Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: Results of the TREE Study","volume":"26","author":"Hochster","year":"2008","journal-title":"J Clin Oncol"},{"key":"key20230807130139_b26-ol-26-2-13915","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1177\/0022034515621740","article-title":"MALT1 Inhibition of oral carcinoma cell invasion and ERK\/MAPK Activation","volume":"95","author":"Chiba","year":"2016","journal-title":"J Dent Res"},{"key":"key20230807130139_b27-ol-26-2-13915","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13046-015-0225-7","article-title":"Cancer-related CD15\/FUT4 overexpression decreases benefit to agents targeting EGFR or VEGF acting as a novel RAF-MEK-ERK kinase downstream regulator in metastatic colorectal cancer","volume":"34","author":"Giordano","year":"2015","journal-title":"J Exp Clin Cancer Res"},{"key":"key20230807130139_b28-ol-26-2-13915","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ejca.2021.03.043","article-title":"The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors","volume":"150","author":"Corti","year":"2021","journal-title":"Eur J Cancer"},{"key":"key20230807130139_b29-ol-26-2-13915","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13045-019-0738-1","article-title":"Mismatch repair deficiency\/microsatellite instability-high as a predictor for anti-PD-1\/PD-L1 immunotherapy efficacy","volume":"12","author":"Zhao","year":"2019","journal-title":"J Hematol Oncol"},{"key":"key20230807130139_b30-ol-26-2-13915","doi-asserted-by":"publisher","first-page":"e0222548","DOI":"10.1371\/journal.pone.0222548","article-title":"A MALT1 inhibitor suppresses human myeloid DC, effector T-cell and B-cell responses and retains Th1\/regulatory T-cell homeostasis","volume":"15","author":"Dumont","year":"2020","journal-title":"PLoS One"},{"key":"key20230807130139_b31-ol-26-2-13915","doi-asserted-by":"publisher","first-page":"344","DOI":"10.3390\/biomedicines10020344","article-title":"The Paracaspase MALT1 in Cancer","volume":"10","author":"Gomez Solsona","year":"2022","journal-title":"Biomedicines"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T10:04:33Z","timestamp":1691402673000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2023.13915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,15]]},"references-count":31,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,6,15]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2023.13915","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,15]]},"article-number":"329"}}